News

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good ...
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...
Poor investigator site selection remains a significant driver of spiraling costs and inefficiencies in clinical development.